TVA Medical | Clinical Studies | Enrollment Complete

Enrollment Complete

The Novel Endovascular Access Trial (NEAT) is a prospective study to characterize the safety and effectiveness of the minimally-invasive everlinQ™ System to create an AV fistula for hemodialysis patients. Study is being conducted outside the United States in Canada, Australia, and New Zealand.

 

Primary Objective:

To characterize the safety of the everlinQ System in patients with CKD who require a hemodialysis vascular access.

 

Get More Information Here

 

NEAT was approved by Health Canada (#213116/#223684) and  the Australian TGA (# 2014/0764)